Lucoderm 5mg Tablet contains Trioxasalen, a psoralen derivative used primarily in the treatment of vitiligo and psoriasis. Trioxasalen acts by intercalating into DNA and, upon exposure to ultraviolet A (UVA) light, forms cross-links that inhibit DNA synthesis and cell proliferation. This photochemotherapeutic mechanism helps to restore pigmentation in depigmented skin patches by stimulating melanocyte activity. Lucoderm is indicated for patients with stable vitiligo and chronic plaque psoriasis unresponsive to conventional therapy. The recommended dosage involves oral administration of 5mg tablets, typically taken 1-2 hours before UVA exposure, with treatment frequency and duration tailored according to clinical response and tolerance. Caution is advised to avoid excessive UVA exposure to minimize the risk of phototoxic reactions, including erythema and blistering. Patients should be monitored regularly for adverse effects such as gastrointestinal discomfort, photosensitivity, and potential long-term risks like photoaging or carcinogenesis. Lucoderm is contraindicated in patients with a history of hypersensitivity to psoralens, hepatic impairment, or active malignancies. Adequate hydration and protective measures against sunlight are essential during therapy. This medication should be used under strict medical supervision, ensuring appropriate UVA dosage and patient compliance to optimize therapeutic outcomes while minimizing risks.